The vaccine targets two variants of Cutibacterium acnes — the bacterium that often causes the skin condition — HylA and HylB. By neutralizing these variant-produced enzymes, the vaccine was found to reduce inflammation while simultaneously avoiding the healthy bacterial enzymes, according to the research, which was published Dec. 5 in Nature Communications.
Although the trials were in mice and authors of the study note that additional clinical trials are necessary to compare effectiveness in humans, researchers are working toward developing “a therapy that’s much more tailored toward exactly what we know causes acne, rather than just generically blocking inflammation,” George Liu, MD, PhD, a professor and chief of the Division of Pediatric Infectious Diseases at UC San Diego School of Medicine, said in the release.
“We hope that by understanding how bacteria induce acne, we can come up with a single or combination vaccine that would take care of acne much more effectively than we can right now,” he added.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
